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Abstract 
Using three types of in vitro endothelial cell barrier models, we investigated the 
direct effects and mechanisms of morphine on vascular permeability. Our current studies 
illustrate LPS induces permeability across these VEC barriers, and is significantly 
enhanced when co-treated with morphine, displayed using the [14CJ-inulin paracellular 
marker. Incubation with morphine alone induces permeability in a concentration­ 
depeodent manner, and is not blocked by the addition of naloxone. Morphine enhances 
the detrimental effects of LPS on cell viability and alone also decreases endothelial cell 
viability, concentration-dependently, which is also not affected by naloxone, as 
demonstrated by the trypan blue exclusion assay. Using 4',6-diarnidino-2-phenylindole 
(DAPI) nuclear stain, we reveal LPS- and morphine-induced cell death is through an 
apoptotic mechanism. Morphine-induced apoptosis is concentration-dependent and not 
blocked by naloxone once again, and cotreatment with LPS synergizes to induce 
enhanced apoptosis. Morphine has been shown to induce Fas-mediated apoptosis in 
immune cells (Yin et al., 1999); however, our VEC models demonstrate a Fas­ 
independent apoptotic mechanism. Lastly, we confirm that pretreatment of the 
monolayer with morphine enhances viral penetration, using The Amplicor® Viral RNA 
Detection Assay. These results suggest that morphine enhances permeability and viral 
penetration across the vascular endothelium by promoting apoptosis, via a Fas­ 
independent pathway. This study reveals insight as to how morphine exposure may 
enhance HIV -1 penetration and further implicate the effects of endotoxins on these 
physiological barriers. 
Introduction 
The vessels of the vascular system arc lined by a continuous mono layer of endothelial 
cells containing intercellular adherent and tight junctions. These specialized junctions 
function as a barrier against uncontrolled paracellular permeability (Kevil et al., 1998; 
Rubin and Staddon, 1999; Li and Mrsny, 2000). Thus, the vascular endothelial cell 
(VEC) barrier provides a crucial interface between the circulating blood and the 
underlying tissues (Hoek, 1992), and serves as a boundary to protect vital organ systems 
from invasion by micropathogens such as the HIV-I virus (Baba et al., 1988; Zietz et al., 
1996; Notter, 1999). Mechanical stress, intlanunation, or exogenous factors such as 
drugs of abuse, including the opiate, morphine, may disrupt the VEC layer, leading to 
edema and significant damage to the underlying tissues. 
Previous studies have shown that chronic morphine exposure increases the 
penetration of microorganisms across the epithelial lining of the GI tract (Hilberger et al., 
1997; Macfarlane et al., 2000; Bannerman and Golblum, 1997). These studies suggest 
that morphine may modulate the permeability of the GI tract epithelium, which contains 
intercellular junctions similar to VEC. However, the specific cellular and molecular 
mechanisms underlying morphine's effects on the VEC barrier still need to be elucidated. 
One mechanism by which morphine may alter VEC permeability is through the 
promotion of programmed cell death or apoptosis. Apoptosis, which is a normal cellular 
process, may be induced prematurely by morphine's activation of certain intracellular 
signals, such as the pro-apoptotic Fas-dependent pathway. A recent study reported that 
morphine induces the expression of the death receptor, Fas, in immune cells (Yin et al., 
1999). The Fas-dependent pathway is initiated by the binding of the Fas-Ligand (FasL) 
to the Fas receptor, thus, activating the Fas-Associated Death Domain (FADD) of the 
receptor. In turn, a cascade of caspases is triggered, mediating apoptotic cell death. In 
addition, a soluble form of the receptor, sFas, can exist in circulation, and has been 
reported to block Fas-dependent apoptosis (Cheng et al., 1994). 
Bacterial LPS is a complex glycolipid isolated from the cell walls of Gram-negative 
bacteria. LPS acts as a potent endotoxin, leading to an acute inflammatory response that 
can ultimately result in endotoxic shock (Roy et al., 1999). LPS has been shown to 
induce production of an array of immune mediators, including the pro-apoptotic proteins, 
FasL and sFas, in sinusoidal endothelial cells (Muschen et al., 1998). 
Synergistic effects of morphine and LPS have been observed for various parameter, 
of immune responses (Roy et al., 1999). For example, chronic exposure to morphine has 
been shown to enhance LPS induced production of pro-inflammatory cytokines that can 
increase leukocyte adhesion to endothelial cells (Chang, 2001). These cytokines have 
been shown to enhance the permeability of the VEC barrier (Fiala et al., 1997). 
In this study, we investigated whether morphine's actions on endothelial cells could 
augment the effects of LPS and enhance the permeability of the VEC barrier, thus, 
allowing viruses, such as lllV-1, to penetrate these physiological barriers. We also 
examined the mechanisms of in vitro endothelial cell death produced by LPS and 
morphine, including the involvement of the Fas/FasL system. 
Methods 
Ch,mica/s and reagents. Morphine sulfate-pentahydrate, naloxone-bydrochloride, LPS 
from Escherichia coli, [14C]-carboxylated inulin, Dulbecco's phosphate buffered saline 
solution (DPBSS), and 4',6-diamidino-2-phenylindole (DAPI) nuclear stain were all 
purchased from Sigma Chemical Co. (St. Louis, MO). Trypan blue solution (0.2%) was 
purchased from GibcoLife Technologies, Inc (Rockville, MD). Recombinant human 
Fas/FC Chimera (soluble Fas protein) was purchased from R & D Systems, Inc. 
(Minneapolis, MN). Fas-Ligand recombinant protein was purchased from Oncogene 
Research Products (Cambridge, MA). PRG-2 trypsin/EDT A solution for the rodent 
endothelial cell line was purchased from Cell Systems, Inc. (Kirkland, WA). 
Cell cultures. Low passage (3"' or 4"') human coronary artery (hCAEC) and human brain 
microvascular (hBMVEC) endothelial cells were purchased from Biowhittaker/Clonetics 
(Walkersville, MD). Cells were cultured in Clonetics EGM-2MV Bullet Kit media 
supplemented with EGM-2 MY, and maintained at 37° C in a humidified 5% C02 
incubator. A Reagent Pack (Biowhittaker) containing Hepes buffered saline solution, 
trypsin/EDT A solution, and trypsin neutralizing solution was also used for culturing the 
human endothelial cell lines. Immortalized rat brain microvascular endothelial cells 
(rBMVEC), generously provided by Dr. D.B. Stanimirovic and Dr. A. Muruganandam 
(National Research Council of Canada), were maintained as previously described 
(Morley et al., 1998). 
In vitro VEC barrier model. An in vitro VEC barrier model was constructed as 
described (Fiala et al., 1997) using hBMVEC, rBMVEC, and hCAEC cells, passage 
numbers 5-8. Briefly, the endothelial cells were seeded at a density of20,000 
cells/0.3mL into a cell culture insert (8.0 µm pore size) housed in a 24-well tissne culture 
plate (Fisher Scientific, Springfield, NJ), containing I mUwell of culture medium. 
For the LPS experiments, cells at 100% confluency, the medium in the top insert 
chamber was replaced with either 0.3 mL of fresh medium (for controls), 0.3 mL of fresh 
medium containing LPS (I, 10, or 100 µg/mL), or 0.3 mL of fresh medium containing 10 
µM morphine plus 10 µg/mL LPS. For the morphine experiments, the medium in the 
upper chamber was replaced with morphine-supplemented medium (I, I 0, or I 00 µM). 
The medium in all the lower chambers was replaced with 1.0 mL of fresh medium, and 
the plates were incubated for 24 hat 37° C. Naloxone sensitivity was determined by pre­ 
treating the cells in the top chamber with 0.3 mL of fresh medium containing 100 µM 
naloxone for 20 min. The naloxone-supplemented medium was then replaced with 0.3 
mL of morphine (IO µM)-supplemented medium, and the plates were incubated for 24 h 
at 37° C. 
At the end of each treatment period, the medium in the upper chamber was replaced 
with 0.3 mL of fresh medium containing [14CJ-carboxylated inulin, and the medium in 
the bottom chamber was replaced with I mL of fresh medium. The cells were incubated 
at 37' C for an additional 2 h to allow for diffusion. Fifty microliters of the medium from 
each top and bottom chamber were then collected, mixed with liquid scintillation 
cocktail, and counted in a liquid scintillation counter. The permeability coefficient 
(cm/min) for [14C]-inulin (MW 5000) was calculated using the formula previously 
described by Fiala et al. (1997): 
{VI (A* D)} * {pR/ pT }, 
where V = volume of the receptor chamber (1.0 cm'), A= area of the cell monolayer on 
the membrane (0.35 cm2), D = initial amount of the marker molecule in the donor 
chamber, pR/ pT = amount of the marker molecule in the receiver solution (pT = I hr. or 
4hr.) 
After each experiment, the upper chambers were stained with crystal violet and 
observed with an Olympus Model IMT-2 inverted bright-phase compound microscope to 
ensure minimal damage to the confluent monolayers. 
Viability studies. The primary endothelial cells were seeded at a density of 50,000 
cells/well (passages 5-9) into 6-well plates containing 4 mUwell of fresh medium, and 
grown until -70% confluent. Fresh medium (for controls), or medium containing 
morphine (I, IO, or 100 µM), naloxone (100 µM), morphine (IO µM) plus naloxone, LPS 
(IO µg/mL), or morphine (IO µM) plus LPS (IO µg/mL) was added, and the cells were 
incubated for an additional 24 hat 37° C. Tue monolayers were examined with a phase 
contrast microscope to ensure that they remained intact. The supernatant was discarded, 
and each well was washed twice with Hepes buffered saline solution 
(Biowhittaker/Clonetics, Walkersville, MD). The human endothelial cells were detached 
with trypsin/EDT A, and the trypsin was inactivated with trypsin neutralizing solution. 
PRG-2 (Passage Reagent Group) trypsin/EDTA solution was used to detach the rodent 
endothelial cell monolayers, which was then inactivated by addition of twice the amount 
of cell culture medium. The cells were centrifuged at 700 rpm at room temperature for 
five minutes, and resuspended in fresh culture medium. Cell viability was determined on 
a hemacytometer by the trypan blue exclusion assay. 
Nuclear staining assay. All three endothelial cell types (passages 6-9) were grown to 
70% confluence on round glass coverslips (Fisher Scientific) in 24 well-plates. One 
milliliter of fresh medium containing the appropriate treatment was added in 
quadruplicate, and the cells were incubated for an additional 24 hat 37° C. The final 
concentrations of the treatments were: 10 µM morphine ± 100 µM naloxone, 100 µM 
naloxone, or 10 µg/mL LPS ± 10 µM morphine. At the end of the 24 h incubation, the 
cells were stained with 4',6-diamidino-2-phenylindole (DAPI), which intercalates DNA, 
and, under UV light, the condensed, irregularly nuclei of apoptotic cells were 
differentiated from the large, round nuclei of normal cells. Briefly, DAPI staining was 
performed by fixing the cells onto coverslips with 4% paraformaldehyde for 5-8 min, 
rinsing the cells 3 times with PBS, then penneabilizing the cells with 95% ethanol/5% 
acetic acid for 5-8 min. The cells were then rinsed 3 times with PBS, and incubated in 
the dark at room temperature with DAPI (final concentration - 300 nM in PBS) for 1-3 
min. After 3 PBS rinses, the coverslips were mounted with Pennount onto microscope 
slides. The cells were examined with an Olympus BX40 system microscope with an 
Olympus BX-FLA reflected light fluorescence attachment at an excitation wavelength of 
358 run and an emission wavelength of 461 run, and photographed with an Olympus 
camera (Model number C-35AD-4) and 400 speed Kodak film with an exposure time of 1 
minute. 
Assessment of th• Fas/Fas-Ligand pathway. The hBMVEC cell monolayers (passage 8- 
10) were grown on round glass coverslips in 24-well plates, as described above, and 
maintained at 37° C in a humidified environment. When the cells reached 700/o 
confluence, the medium was replaced with 900 µL of fresh medium and I 00 µL of 
medium containing the appropriate treatment ( 4 wells/treatment). The final 
concentrations of the treatments were: 200 ng/mL FasL alone, 200 ng/mL FasL ± SO 
ng/mL sFas, 10 µM morphine± SO ng/mL sFas, 10 µg/mL LPS ± SO ng/mL sFas, or SO 
ng/mL sFas alone. The cells were incubated for 24 hat 37° C, then analyzed for 
apoptotic nuclei by fluorescent microscopy using the DAPI nuclear staining assay. 
HIV-I penetration assays. These experiments were performed by our collaborators, Ors. 
Gujuluva and Fiala, of the department ofNeurology at UCLA School of Medicine, Los 
Angeles, California. Briefly, the VEC barrier model was constructed using the hCAEC 
cell line, as described previously in the in vitro VEC barrier models used for the [14C]­ 
inulin permeability assays (Fiala et al., 1997). When the cells reached 70% confluence, 
the macrophage-tropic virus strain, HIV-1,R.fl. (150,000,000 RNA copies), was added to 
the upper chamber with control vehicle, and incubated at 37' C for either 2 h or 24 h. To 
determine the effects of morphine on viral penetration across the VEC barrier, either 
morphine (10 µMor 100 µM), or naloxone (100 µM) and morphine (10 µM) was added 
to the upper chamber and incubated at 37° C for 24 h. Approximately 150,000,000 RNA 
copies of the HIV-I virus was then added to the upper chamber, and the plate was again 
incubated at 37' C for 24 h. After incubation, 50 µL samples were collected from both 
the upper and lower chambers, and the number of HIV RNA copies was determined 
according to Fiala et al. (1997) using the Amplicor® HIV -1 monitor test developed by 
Roche Corp. Diagnostic Laboratories (Nutley, NJ). The amount of virus in the morphine­ 
treated samples was determined, and compared to the control vehicle standard. This 
experiment was repeated at least twice with reproducible results. 
Statistical analysis. For all studies, statistical significance of the results were determined 
using ANOVA or the Student's I-test using the GraphPAD InStat software (GraphPad 
Software, San Diego, CA). Post-hoc statistics were computed using adjusted t-tests with 
p-values corrected by the Bonferroni method. Significance was evaluated using a 
standard 95% confidence interval (p<0.05). Individual samples were tested in triplicate 
or quadruplicate for each experiment, and each experiment was repeated at least twice 
with similar results. 
Results 
Morphine's effects on LPS-induced permeability of the VEC barrier. The effects of the 
bacterial endotoxin, LPS, on the hCAEC VEC barrier model were examined by 
determining the penneability of the hCAEC monolayer to [14CJ-inulin. Pre-treatrnent of 
the hCAEC with I, 10, and 100 µg/mL LPS for 24 h significantly increased [14CJ-inulin 
permeability in a concentration-dependent manner (Figure IA). Co-treatrnent of the 
model with IO µM morphine plus IO µg/mL LPS enhanced [14C]-inulin permeability 
compared to LPS alone (Figure I B). 
Morphine's effects on three different VEC barrier models were determined by pre­ 
treating the hCAEC(A), hBMVEC (B), and rBMVEC (C) monolayers for 24 h with 
either morphine alone (I, IO, or 100 µM), 100 µM naloxone alone, or 10 µM morphine 
plus naloxone, then examining [14C]-inulin permeability (Figure 2). Treatment with 
either morphine or naloxone alone increased [14C]-inulin permeability (Figure 2), and co­ 
treatment with morphine plus na1oxone resulted in an additive effect on [14C]-inulin 
permeability in all three of the endothelial cell lines tested (Figure 2). 
Morphine's effects on cell viability of endothelial cells. To determine if the change in 
the VEC penneability produced by LPS and morphine occurred as a result of endothelial 
cell death, the viability of the hCAEC (A), hBMVEC (B), and rBMVEC (C) cells was 
examined. Treatment with either morphine (JO µMand 100 µM) or naloxone (100 µM) 
significantly decreased the viability of all three endothelial cell lines compared to control 
(p<0.005, Figure 3). Co-treatment with morphine (JO µM) plus naloxone lowered cell 
viability in an additive manner compared to morphine alone (Figure 3). 
LPS (IO µg/mL) treatment decreased the viability of the hCAEC, hBMVEC, and 
rBMVEC cells (Figure 4A, B, and C, respectively) compared to untreated control 
cultures. All three endothelial cell types co-treated with morphine (IO µM) plus LPS had 
a significantly lower percentage of viable cells compared to LPS treatment alone (Figure 
4). 
Apoplolic effects of morphine on endothelial cells. Decreased cell viability can result 
from either necrosis (physical or chemical damage to cells) or apoptosis (programmed 
cell death). Necrosis due to physical damage was ruled out because microscopic 
examination of the cell monolayers showed that the cells remained morphologically 
intact following morphine treatment ( data not shown). Apoptosis can be identified by 
characteristic morphological changes that occur in the nucleus of cells. Using DAPI 
nuclear staining, the nuclear morphology of the hBMVEC treated with IO µM morphine 
with and without IO µg/mL LPS was examined. The condensed, irregular nuclei of 
apoptotic cells were then differentiated from the large, round nuclei of normal cells. 
Untreated control hBMVEC cells contained morphologically normal nuclei (Figure SA); 
whereas apoptotic nuclei were observed in the morphine- and LPS-treated cells (Figure 
SB and C, respectively). Co-treatment with morphine plus LPS resulted in both cells 
with apoptotic nuclei and cells with normal nuclei (Figure SD). 
The percentage of apoptotic cells was calculated for the hCAEC (A), hBMVEC (B), 
and rBMVEC (C) following treatment with IO µM morphine, 100 µM naloxone, 
morphine plus naloxone, IO µg/mL LPS, or morphine plus LPS. Morphine treatment 
induced apoptosis in all three endothelial cell types; this effect was not blocked by 
naloxone (Figure 6). In fact, the number of apoptotic cells was additive following 
treatment with morphine plus naloxone compared to morphine treatment alone (Figure 6), 
which is consistent with the decreased cell viability observed with morphine plus 
naloxone treatment. 
Treatment with LPS also resulted in apoptosis of the endothelial cells, which was 
significantly enhanced by co-treatment with morphine (Figure 6). 
Morphine's ejfecls on Fas-mediaJed endothelial cell apoptosis. Binding ofFasL to the 
Fas receptor has been shown to promote apoptosis. The soluble fonn of Fas, sFas, is 
thought to inhibit the Fas/FasL apoptotic signaling pathway by blocking the binding of 
FasL to the Fas receptor (Cheng et al., 1994). We, therefore, investigated if the Fas 
pathway could be involved in morphine's apoptotic effects on the VEC barrier. 
hBMVEC cells treated with either 200 ng/mL FasL or 50 ng/mL sFas underwent 
significant apoptosis when compared to untreated control monolayers (p<0.005, Figure 
7 A). However, co-treatment of the monolayer with FasL plus sFas inhibited apoptosis 
(Figure 7 A). Consistent with our previous results, treatment with 10 µM morphine alone 
induced apoptosis (Figure 7A); whereas co-treatment with morphine plus sFas induced 
apoptosis in an additive manner (Figure 1 A). 
Treatment with IO µg/mL LPS also induced significant apoptosis (Figure 7B). 
However, this apoptotic effect was blocked by co-treatment with LPS plus sFas (Figure 
7B). 
Morphine's effects Oii HlV-1 pe11etNtlo11 of 1111;,, 1'ilro VEC barrier. Since exposure to 
morphine resuhed in a significant increase in VEC petmeability, we then investigated if 
morphine could alrect the penetration of viral particles, such as lilV-1, through the VEC 
barrier. Using the uhrasensitive Amplicor•viral RNA detection assay, we determined 
the average number of viral RNA copies Iha! peoetratod into the lower chamber of the 
bCAEC barrier model at 2 b and 24 h after addition ofIDV -1 to the upper chamber 
(Figure 8). A significant number of viral RNA copies penetrated into the lower chamber 
at 24 h compared to the number at 2 h (p<0.005). Treatment with morphine (IO µM or 
100 µM) significantly increased the average number of!IlV-1 RNA copies penetrating 
into the lower chamber in a dose-OepCDdc:ot manner (Fig= 8). 
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Discussion 
The vascular endothelial cell (VEC) barrier is important in providing an impermeable 
interface between the cireulating blood and the underlying tissue. Structurally, this 
barrier is critical for protecting the host against pathogenic microorganisms such as the 
HIV-I virus. However, the VEC can be compromised by infection and chronic opioid 
abuse. In this study, we explored the mechanisms by which morphine enhances LPS­ 
induced permeability of VEC barriers and promotes HIV- I penetration through those 
barriers. 
LPS is a bacterial endotoxin that affects the integrity of the vascular endothelial 
lining (Bannerman and Goldblum, 1997). Under pbase contrast light microscopy, there 
are no obvious differences in the morphology of these cells; all three cell types, 
rBMVEC, hBMVEC, and hCAEC grow into a confluent monolayer and present contact 
inhibition of cell growth. In our studies, both LPS and morphine decreased VEC viability 
and increased the [14C]-inulin permeability in these three endothelial cell types tested. 
Furthermore, morphine co-treatment significantly enhanced LPS-induced permeability of 
the VEC, suggesting that the detrimental effects of LPS on the VEC barrier could be 
significantly greater in the presence of morphine. 
We then investigated the mechanism by which VEC viability and permeability could 
be affected by morphine and LPS. Cell death can occur as a result of either necrosis or 
apoptosis (Farber, 1994; Tromp et al., 1997). Necrosis is characterized by cell membrane 
swelling and bl ebbing, and the simultaneous death of large numbers of cells. Apoptosis 
is programmed cell death that results from intracellular signal transduction pathways, and 
usually involves only a single or a few isolated cells at any given time. Nuclear staining 
with DAPI and morphological examination confirmed that the decrease in cell viability 
following treatment with either morphine or LPS alone, and in combination was due to 
apoptosis, and not necrosis. Such morphine-induced programmed cell death could 
certainly contribute to enhanced VEC penneability and increase the possibility of 
penetration by 1-IlV-l through the VEC barriers. 
Preliminary studies showed that FasL, the natural ligand for Fas, induced apoptosis in 
our VEC in a concentration-dependent manner, and that morphine pre-treatment 
enhanced FasL-induced apoptosis, confirming the expression of a functional Fas receptor 
in our cell types (data not shown). Morphine has been shown to induce expression of Fas 
in a T-cell hybridoma (Al.I), in mouse splenocytes, and freshly isolated human 
peripheral blood lymphocytes (Yin et al., 1997). Taken together, these results suggested 
that morphine may prime the VEC to undergo FAS-mediated apoptosis. The soluble 
fonn of Fas, sFas, reportedly blocks Fas-dependent apoptosis (Cheng et al., 1994). In 
this study, we, therefore, used sFas to examine if morphine's apoptotic effects were Fas­ 
dependent. As expected, sFas did inhibit FasL-induced apoptosis. Furthermore, when 
the VEC monolayer was co-treated with LPS and sFas, apoptosis was inhibited, 
suggesting that LPS-induced apoptosis is mediated via a Fas-dependent pathway. 
Unexpectedly, sFas alone induced apoptosis of the endothelial cells, and co-treatment 
with morphine resulted in increased rather than decreased apoptotic effects. These data 
suggest that the molecular mechanisms underlying morphine-induced apoptosis in the 
VEC monolayer are mediated through Fas-independent pathways although the VEC has 
demonstrated functional Fas/Fas-L mediated apoptotic pathways. Our studies are 
consistent with previous studies showing variable data regarding the susceptibility of 
vascular endothelial cells to Fas-mediated cell death and the expression of Fas-regulatory 
components (Walsh and Sala, 1999). Another possible mechanism by which morphine 
may affect endothelial cell permeability is through the mu opioid receptor pathway. The 
presence of opioid receptors on endothelial cells has been shown by our laboratory (Vidal 
et al., 1998) and others (Stefano et al., 1995; He et al., 2000). While expression of mu 
opioid receptor mRNA has been demonstrated in endothelial cells by both semi­ 
quantitative and competitive RT-PCR (Vidal et al., 1998; Stefano et al., 1995), mu-opioid 
binding sites have not been identified. Furthermore, in our study, morphine's actions 
were not reversed by naloxone, a mu opioid receptor antagonist. Although we do not 
completely exclude the possibility that morphine's effects on [14CJ-inulin permeability, 
cell viability, and apoptosis are mediated via opioid receptors, the data suggest that 
morphine may act on these endothelial cells via a distinct, separate pathway, especially 
considering a study by Melzig et al. (1998) showing binding of ['HJ-morphine within the 
nuclei of endothelial cells. These experiments demonstrate a mechanism of action for 
morphine that is not mediated via opioid receptors, but rather binding to a separate 
membrane or nuclear fraction of the endothelial cells. Therefore, the underlying 
mechanism of morphine, as reported here, still remains to be clarified. 
The VEC barrier is one of the defense mechanisms through which vital organs are 
protected from attack by pathogenic viruses such as HIV-I. While HIV-I penetration 
through our hCAEC barrier model was limited when exposure duration was short, the 
penetration of HN-1 through the VEC barrier was significantly increased following 
prolonged exposure to virus. These results are consistent with a previous report, which 
examined an in vitro blood-brain barrier model constructed from endothelial cells 
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isolated from micro vascular vessels (1998). In addition, pre-treatment of the hCAEC 
barrier model with morphine enhanced HIV-I penetration. Taken together, these findings 
suggest that the VEC barrier breaks down with prolonged exposure to HIV-I, and that the 
integrity of the VEC barrier could be compromised further by the presence of morphine. 
Consequently, in opioid addicts or in patients chronically treated with morphine for pain 
relief, the VEC barrier may be compromised, allowing enhanced penetration of 
pathogenic microorganisms, such as the HIV -1 virus. 
HIV- I -associated encephalitis and cardiomyopathy are characterized by the 
pronounced entry of the virus into the organ tissue environment (Fiala et al., 1997; 
Persidsky et al., 1997). The increased penetration of cell-free or cell-associated 
pathogens that results from endothelial damage may contribute to the pathogenesis 
associated with HIV- I infection (Berger et al., 1999). In the presence of morphine, these 
cell-free viruses may penetrate the physiological VEC barriers more effectively. Our 
results provide some insight into the mechanisms underlying how morphine exposure 
may enhance HIV-I penetration through VEC barriers, and the detrimental effects that 
endotoxins, such as LPS, may have on these physiological barriers. 
Swnnuuy 
The VEC berrier is one of the defense mechanisms by which vital organs are 
protected from attack by pathogenic viruses such as HIV-I. Our findings suggest that the 
VEC barrier breaks down with prolonged exposure to HIV-I, and that the integrity of the 
VEC bonier is compromised further in the presence of morphine. Consequently, in 
opioid addicts or in patients chronically treated with morphine for pain relict; the VEC 
berrier may be breached, allowing this enhanced penetration of pathogenic 
microorganisms, such as the HIV-I virus. Our resuhs provide somo in.sight into the 
mechanisms underlying how morphine exposure may enhsnce HIV-I penetration through 
VEC barriers, and the detrimental effi:cts that endotoxins, such as LPS, may have on 
these phY5iological berriers. 
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